The drug maker Biogen reported Thursday that its controversial drug against Alzheimer's disease Aduhelm
The company has not
Industry analysts expected the meadrug starts modestly. Many insurers have yet to decide how to cover it. Administration sites - usually memory clinics that serve patients with cognitive problems - have been slowed down by the complexity of administering the drug, which must be administered as a monthly intravenous infusion.
The federal agency that administers Medicare announced earlier this month that it will launch a month-long review to determine if 'There was a need to standardize drug coverage across the country, a step that could restrict which patients receive it. In the meantime, some Medicare Advantage plans, an alternative to traditional health insurance offered by private insurance companies, have already approved patients to receive the drug, the company said.
The leaders of Biogen have passed much of the earnings call on Thursday to defend Aduhelm and the process that led to its approval.
Drug approval on the month The latter has attracted close scrutiny, in large part because there is little evidence that it can help patients. Some large medical centers have decided not to offer it , and two congressional committees are investigating the drug's approval and price. Critics also queried the close collaboration between Biogen and the Food and Drug Administration in preparation for approval.